What Is Travere Therapeutics, Inc. (TVTX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Travere Therapeutics, Inc.'s intrinsic value is estimated at $15.89. Trading at its current price of $56.74, the valuation engine raises significant caution: 10 of 11 models flag downside risk, projecting an average implied return of -72.0%. The most optimistic model, PWERM, places fair value at $57.31 (+1.0%), while Sentiment SOTP — the most conservative — estimates $2.36 (-95.8%). This +96.8% gap reflects genuine analytical uncertainty about Travere Therapeutics, Inc.'s intrinsic worth. Among models with highest confidence, Markov DDM lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About TVTX?
11 of 13 models are currently active for TVTX. Of these, 1 model suggests upside while 10 models suggest overvaluation. The Bayesian DCF estimates TVTX's intrinsic value at $15.68, implying -72.4% downside from the current price. See which stocks rank higher →
How Does TVTX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, TVTX ranks #110 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Travere Therapeutics, Inc., metrics like biosimilar competition timeline provide important context that general-purpose valuation models may underweight.
Is TVTX a Value Trap?
CirclFi's Value Trap algorithm assigns TVTX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Travere Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Travere Therapeutics, Inc. scores 6.2 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +96.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every TVTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across TVTX's 11 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad